

## **Product datasheet for SR312966**

#### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

### **DDHD1 Human siRNA Oligo Duplex (Locus ID 80821)**

#### **Product data:**

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

**Quality Control:** Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

 Note:
 Single siRNA duplex (10nmol) can be ordered.

 RefSeq:
 NM 001160147, NM 001160148, NM 030637

UniProt ID: Q8NEL9

**Synonyms:** iPLA1alpha; PA-PLA1; PAPLA1; SPG28

Components: DDHD1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 80821)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

**Summary:** This gene is a member of the intracellular phospholipase A1 gene family. The protein

encoded by this gene preferentially hydrolyzes phosphatidic acid. It is a cytosolic protein with

some mitochondrial localization, and is thought to be involved in the regulation of

mitochondrial dynamics. Overexpression of this gene causes fragmentation of the tubular structures in mitochondria, while depletion of the gene results in mitochondrial tubule elongation. Deletion of this gene in male mice caused fertility defects, resulting from disruption in the organization of the mitochondria during spermiogenesis. In humans, mutations in this gene have been associated with hereditary spastic paraplegia (HSP), also known as Strumpell-Lorrain disease, or, familial spastic paraparesis (FSP). This inherited disorder is characterized by progressive weakness and spasticity of the legs. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by

RefSeq, Aug 2015]







# Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).